Skip to main
  1. Stocks
  2. Boston Scientific
  3. Forecast
BSX

Boston Scientific (BSX) Stock Forecast & Price Target

Boston Scientific (BSX) Analyst Ratings

Based on 23 analyst ratings
Buy
Strong Buy 35%
Buy 43%
Hold 22%
Sell 0%
Strong Sell 0%

Bulls say

Boston Scientific is supported by a diversified, high-growth portfolio that has reduced reliance on commoditized cardiac rhythm management and drug-eluting stents, while expanding into faster-growing MedTech markets through innovation and tuck-in M&A. Its 2023 revenue of $5.138B and positive Q3 operating performance underscore broad portfolio strength, with interventional cardiology, ICVTx, neuromodulation, and multiple new product launches providing several shots on goal as WATCHMAN and EP headwinds are expected to trough around 2027. The company’s healthy balance sheet, investment-grade credit, and disciplined capital allocation—along with about 36% of sales from foreign markets and an estimated ~$500M in restructuring savings—support long-term EPS growth and margin recovery.

Bears say

Boston Scientific is facing a materially weaker fundamental setup as 2026 guidance was cut to 4.25% reported revenue growth and $3.16-$3.18 in EPS, below Street expectations, while Q4 sales are now expected to decline 1-3% and EPS to fall to $0.77-$0.79. The bearish thesis is reinforced by margin compression from an unfavorable product mix, supply chain and quality investments, and the cyberattack, all of which pressure gross margin below 2025’s 70.6% and operating margin to 27.6%. Looking beyond 2026, management’s more cautious 2027 view, delays to FarawaveUltra and Faraflex, and ongoing share loss in EP and Watchman suggest growth and earnings could remain challenged well into 2028.

Boston Scientific (BSX) has been analyzed by 23 analysts, with a consensus rating of Buy. 35% of analysts recommend a Strong Buy, 43% recommend Buy, 22% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Boston Scientific and is not a guaranteed prediction by Public.com or investment advice.

Boston Scientific (BSX) Analyst Forecast & Price Prediction

Get the latest Boston Scientific (BSX) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in Boston Scientific (BSX)

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Boston Scientific (BSX) Forecast

Analysts have given Boston Scientific (BSX) a Buy based on their latest research and market trends.

According to 23 analysts, Boston Scientific (BSX) has a Buy consensus rating as of Nov 19, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $60.17, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $60.17, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Boston Scientific (BSX)


Boston Scientific (BSX) Analyst Forecast & Price Prediction

Get the latest Boston Scientific (BSX) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in Boston Scientific (BSX)

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.
Uncover BSX stock data and trends